Suppr超能文献

4-(苯乙炔基)-6-苯基-1,4-二氢吡啶作为高选择性A3腺苷受体拮抗剂的构效关系

Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.

作者信息

Jiang J, van Rhee A M, Chang L, Patchornik A, Ji X D, Evans P, Melman N, Jacobson K A

机构信息

Molecular Recognition Section, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.

出版信息

J Med Chem. 1997 Aug 1;40(16):2596-608. doi: 10.1021/jm970091j.

Abstract

4-(Phenylethynyl)-6-phenyl-1,4-dihydropyridine derivatives are selective antagonists at human A3 adenosine receptors, with Ki values in a radioligand binding assay vs [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)-5'-(N-methylcarbamoyl)adenosine) in the submicromolar range. In this study, structure-activity relationships at various positions of the dihydropyridine ring (the 3- and 5-acyl substituents, the 4-aryl substituent, and 1-methyl group) were probed synthetically. Using the combined protection of the 1-ethoxymethyl and the 5-[2-(trimethylsilyl)ethyl] ester groups, a free carboxylic acid was formed at the 5-position allowing various substitutions. Selectivity of the new analogues for cloned human A3 adenosine receptors was determined vs radioligand binding at rat brain A1 and A2A receptors. Structure-activity analysis at adenosine receptors indicated that pyridyl, furyl, benzofuryl, and thienyl groups at the 4-position resulted in, at most, only moderate selectivity for A3 adenosine receptors. Ring substitution (e.g., 4-nitro) of the 4-phenylethylnyl group did not provide enhanced selectivity, as it did for the 4-styryl-substituted dihydropyridines. At the 3-position of the dihydropyridine ring, esters were much more selective for A3 receptors than closely related thioester, amide, and ketone derivatives. A cyclic 3-keto derivative was 5-fold more potent at A3 receptors than a related open-ring analogue. At the 5-position, a homologous series of phenylalkyl esters and a series of substituted benzyl esters were prepared and tested. (Trifluoromethyl)-, nitro-, and other benzyl esters substituted with electron-withdrawing groups were specific for A3 receptors with nanomolar Ki values and selectivity as high as 37000-fold. A functionalized congener bearing an [(aminoethyl)amino]carbonyl group was also prepared as an intermediate in the synthesis of biologically active conjugates.

摘要

4-(苯乙炔基)-6-苯基-1,4-二氢吡啶衍生物是人类A3腺苷受体的选择性拮抗剂,在放射性配体结合试验中,其对[125I]AB-MECA(N6-(4-氨基-3-碘苄基)-5'-(N-甲基氨基甲酰基)腺苷)的Ki值处于亚微摩尔范围。在本研究中,通过合成方法探究了二氢吡啶环各个位置(3-和5-酰基取代基、4-芳基取代基和1-甲基)的构效关系。利用1-乙氧基甲基和5-[2-(三甲基甲硅烷基)乙基]酯基的联合保护,在5-位形成游离羧酸,从而允许进行各种取代。通过与大鼠脑A1和A2A受体的放射性配体结合试验,测定了新类似物对克隆的人类A3腺苷受体的选择性。腺苷受体的构效分析表明,4-位的吡啶基、呋喃基、苯并呋喃基和噻吩基最多仅对A3腺苷受体具有中等选择性。4-苯乙炔基的环取代(如4-硝基)并未像4-苯乙烯基取代的二氢吡啶那样提供增强的选择性。在二氢吡啶环的3-位,酯对A3受体的选择性远高于密切相关的硫酯、酰胺和酮衍生物。一种环状3-酮衍生物在A3受体上的活性比相关的开环类似物高5倍。在5-位,制备并测试了一系列苯基烷基酯和一系列取代苄基酯。(三氟甲基)-、硝基-和其他带有吸电子基团取代的苄基酯对A3受体具有特异性,Ki值为纳摩尔级,选择性高达37000倍。还制备了一种带有[(氨基乙基)氨基]羰基的功能化同系物,作为生物活性缀合物合成的中间体。

相似文献

引用本文的文献

1
Probing Adenosine and P2 Receptors: Design of Novel Purines and Nonpurines as Selective Ligands.
Drug Dev Res. 2001 Jan-Feb;52(1-2):178-186. doi: 10.1002/ddr.1113.
2
Species dependence of A adenosine receptor pharmacology and function.
Purinergic Signal. 2023 Sep;19(3):523-550. doi: 10.1007/s11302-022-09910-1. Epub 2022 Dec 20.
3
Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.
Mol Divers. 2022 Jun;26(3):1779-1821. doi: 10.1007/s11030-021-10257-9. Epub 2021 Jun 27.
4
A Adenosine Receptors: Protective vs. Damaging Effects Identified Using Novel Agonists and Antagonists.
Drug Dev Res. 1998 Nov-Dec;45(3-4):113-124. doi: 10.1002/(SICI)1098-2299(199811/12)45:3/4<113::AID-DDR5>3.0.CO;2-S. Epub 1999 Mar 1.
5
A Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.
Med Res Rev. 2018 Jul;38(4):1031-1072. doi: 10.1002/med.21456. Epub 2017 Jul 6.
6
Pyran Template Approach to the Design of Novel A Adenosine Receptor Antagonists.
Drug Dev Res. 1999 Dec;48(4):171-177. doi: 10.1002/(SICI)1098-2299(199912)48:4<171::AID-DDR4>3.0.CO;2-5. Epub 2000 Feb 11.
7
Computational studies to predict or explain G protein coupled receptor polypharmacology.
Trends Pharmacol Sci. 2014 Dec;35(12):658-63. doi: 10.1016/j.tips.2014.10.009. Epub 2014 Nov 14.
8
Activation and Desensitization of Rat A-Adenosine Receptors by Selective Adenosine Derivatives and Xanthine-7-Ribosides.
Drug Dev Res. 1998 Jun 1;44(2-3):97-105. doi: 10.1002/(SICI)1098-2299(199806/07)44:2/3<97::AID-DDR7>3.0.CO;2-5.
9
Adenosine A(1) and prostaglandin E receptor 3 receptors mediate global airway contraction after local epithelial injury.
Am J Respir Cell Mol Biol. 2013 Mar;48(3):299-305. doi: 10.1165/rcmb.2012-0174OC. Epub 2012 Dec 6.
10
Structure-activity relationships of 1,4-dihydropyridines that act as enhancers of the vanilloid receptor 1 (TRPV1).
Bioorg Med Chem. 2008 Oct 15;16(20):9349-58. doi: 10.1016/j.bmc.2008.08.048. Epub 2008 Aug 26.

本文引用的文献

1
Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors.
Drug Dev Res. 1996 Nov-Dec;39(3-4):289-300. doi: 10.1002/(sici)1098-2299(199611/12)39:3/4<289::aid-ddr8>3.0.co;2-n.
2
Species Differences in Ligand Affinity at Central A-Adenosine Receptors.
Drug Dev Res. 1994 Sep;33(1):51-59. doi: 10.1002/ddr.430330109.
3
A-adenosine receptors: design of selective ligands and therapeutic prospects.
Drugs Future. 1995 Jul;20(7):689-699. doi: 10.1358/dof.1995.020.07.531583.
10
Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists.
Biochem Biophys Res Commun. 1996 Feb 27;219(3):904-10. doi: 10.1006/bbrc.1996.0331.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验